{"title":"阿特珠单抗诱发的线性IgA大疱性皮肤病:一份病例报告","authors":"Seba Almutairi, Dana Alessa","doi":"10.4081/dr.2024.9923","DOIUrl":null,"url":null,"abstract":"Linear IgA Bullous Dermatosis (LABD) is a rare immune-mediated vesiculobullous disease that was reported to be induced by infections or medications. Atezolizumab is a monoclonal antibody targeting programmed cell death ligand-1 (PD-L1), it has been used to treat multiple cancers. Here, we report a case of drug induced LABD following the administration of Atezolizumab.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Linear IgA bullous dermatosis induced by atezolizumab: a case report\",\"authors\":\"Seba Almutairi, Dana Alessa\",\"doi\":\"10.4081/dr.2024.9923\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Linear IgA Bullous Dermatosis (LABD) is a rare immune-mediated vesiculobullous disease that was reported to be induced by infections or medications. Atezolizumab is a monoclonal antibody targeting programmed cell death ligand-1 (PD-L1), it has been used to treat multiple cancers. Here, we report a case of drug induced LABD following the administration of Atezolizumab.\",\"PeriodicalId\":11049,\"journal\":{\"name\":\"Dermatology Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-02-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/dr.2024.9923\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/dr.2024.9923","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Linear IgA bullous dermatosis induced by atezolizumab: a case report
Linear IgA Bullous Dermatosis (LABD) is a rare immune-mediated vesiculobullous disease that was reported to be induced by infections or medications. Atezolizumab is a monoclonal antibody targeting programmed cell death ligand-1 (PD-L1), it has been used to treat multiple cancers. Here, we report a case of drug induced LABD following the administration of Atezolizumab.